news, Northwind Pharmaceuticals

Northwind Hires John Solhan as CFO

Northwind Pharmaceuticals Adds New Executive

May 2019 – Northwind announces the addition of John Solhan as Chief Financial Officer.

I’ve known John for many years and am thrilled to have him join our team,” said CEO Phillip Berry. “John’s strong financial leadership skills and deep knowledge of the pharmaceutical distribution industry bring tremendous value to our organization, our clinic clients, and our rapidly growing base of patients.”

Solhan joins the Northwind Family after Wellfount Corporation, where he helped grow its remote dispensing business for nursing homes to $100 million. With an extensive background in medical and pharmaceutical financial modeling and management, Solhan has built a career of developing new technologies and new business models for startups and industry disruptors.

“For years I’ve watched Phil and team build Northwind and am excited to have the chance to get on board, expand the model, and help take our industry-leading employer health model to the next level.”

Northwind Pharmaceuticals, founded in Indianapolis in 2008 and headquartered in the historic former St. Bernadette’s Catholic Church and School building, brings a complete pharmaceutical solution to self-funded employers through onsite medication solutions and home delivery of patient ready prescriptions. Northwind’s solutions make a difference for clients, patients, team members, and communities by reducing the cost of healthcare, creating life supporting jobs, and impacting the communities in which we operate.

Schedule a free claims analysis now.

Let’s Talk now

Leader in AI-driven health benefits navigation Healthee partners with Northwind

Katherine Lurk | Mar 28th, 2025
A game-changer for employers looking to cut costs and gain control With healthcare costs continuing to rise, employers are seeking new ways to rein in spending without sacrificing the quality of benefits. This partnership enables Healthee clients to optimize prescription drug management, reducing costs through preferable generic drug pricing, high-touch chronic care programs, and more. … more »

continue reading

Healthcare Storm 2025: What Will It Be?

Phillip Berry | Jan 1st, 2025
When it comes to American healthcare, we’ve become really good at highlighting its failings. Watching the flurry of lamentations, frustrations, denigrations, and prognostications, over the last few weeks, would lead any rational person to believe that nothing is working in our healthcare system. And, not only is it “not working,” many people conclude that it … more »

continue reading

New Drugs to Market – October Update

Phillip Berry | Oct 25th, 2024
The Food and Drug Administration (FDA) approved three novel drug therapies in October. One of those therapies,  Hympavzi (marstacimab-hncq), is a medication indicated for the treatment of patients with Hemophilia A and Hemophilia B. Hympavzi utilizes a new pathway to help reduce the risk of bleeding episodes in patients with Hemophilia, a disease that impacts … more »

continue reading